Astroblastoma – a rare and challenging tumor: a case report and review of the literature

Nawal Hammas 1,2*, Nadia Senhaji 3, My Youssef Alouai Lamrani 1,5, Sanae Bennis 2,6, Elfaiz Mohamed Chaoui 5,7, Hind El Fatemi 1,2 and Laila Chbani 1,2

Abstract

Background: Astroblastoma is a controversial and an extremely rare central nervous system neoplasm. Although its histogenesis has been clarified recently, controversies exist regarding its cellular origin and validity as a distinct entity. Because of its extreme rarity and because its common features are shared with other glial neoplasms, this tumor is prone to misdiagnosis and remains challenging not only in terms of diagnosis and classification but also in the subsequent management. This case report describes a new case of astroblastoma. It discusses clinical, radiologic, pathological, and therapeutic features and differential diagnosis of this rare neoplasm, with a review of the recent literature.

Case presentation: We report the case of an 8-year-old Moroccan girl who presented with a 1-year history of epileptic seizure, headache, and decreased visual acuity. Cranial magnetic resonance imaging revealed a right occipito-temporal mass. A tumor resection was performed and histological examination combined with immunohistochemical study confirmed the diagnosis of low-grade astroblastoma.

Conclusions: Astroblastoma is a very rare primary brain tumor. Its diagnosis is often challenging because of the astroblastic aspects that can be found in astrocytic tumors, in ependymomas, and in non-neuroepithelial tumors. Considerable confusion surrounds its histogenesis and classification. The low incidence rate makes it difficult to conduct studies to examine tumor characteristics.

Keywords: Astroblastoma, Brain neoplasm, Histogenesis, Immunohistochemistry, Differential diagnosis

Background

Astroblastoma is a controversial and an extremely rare central nervous system neoplasm [1–4]. It accounts for 0.45 to 2.8% of all neuroglial tumors and it is mainly located in the cerebral hemispheres of children, teenagers, and young adults [1, 2, 4–9]. It was initially described by Bailey and Cushing in 1926 [10] as a separate glial tumor and further characterized by Bailey and Bucy in 1930 [11]. Although its histogenesis has been clarified recently, controversies exist regarding its cellular origin and validity as a distinct entity, because it shares features of both astrocytomas and ependymomas [1, 5]. In the literature on brain tumor classification, this tumor has been categorized as follows: as a stage in the process of glioma dedifferentiation [12], as an astrocytoma of large cells producing fibers [13], or as a rare tumor, probably originating from tanyocytes or ependymal astrocytes [14, 15]. Finally, it was listed among “other neuroepithelial tumors” in the WHO Classification of Tumours of the Central Nervous System [16]. Astroblastomas can be graded as either a low-grade or high-grade (anaplastic/malignant) variant. This histopathologic subtyping was applied by many pathologists, but has not yet been integrated in the World Health Organization (WHO) classification [3, 17]. Because of its extreme rarity and because its radiologic and histopathologic features are common and shared with other glial neoplasms, this tumor is prone to misdiagnosis and remains challenging.

* Correspondence: nawalhammas@gmail.com
1 Department of Pathology, Hassan II University Hospital, 30000 Fez, Morocco
2 Biomedical and Translational Research Laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco
Full list of author information is available at the end of the article

© The Author(s). 2018. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
not only in terms of diagnosis and classification but also in the subsequent management. The radiologic and histopathologic features help differentiate it from the more common ependymoma and astrocytoma [2, 4, 9].

This case report describes a new case of a young girl with astroblastoma. It discusses clinical, radiologic, pathological, and therapeutic features and the differential diagnosis of this rare neoplasm, with a large review of the literature.

Case presentation

We report the case of an 8-year-old Moroccan girl who presented with a 1-year history of epileptic seizure, headache, and decreased visual acuity. Cranial magnetic resonance imaging (MRI) revealed a right, occipito-temporal, voluminous, well-demarcated mass with a multicystic component and a characteristic bubbly appearance on T2-weighted images and hypointense heterogenous on T1-weighted images. After contrast injection, a strong contrast enhancement was observed. There was a peritumoral edema and a monoventricular left hydrocephaly (Fig. 1). MRI findings suggested a diagnosis of a glial neoplasm.

An incomplete (because of the hemorrhage) tumor resection was performed and microscopic examination revealed a tumor composed of perivascular rosettes of tumor cells (Fig. 2). The nuclei were generally round to oval, without nuclear pleomorphism or mitotic activity (Fig. 3). The tumor was very vascular with thickened and focally hyalinized blood vessel walls (Fig. 4). An immunohistochemical analysis showed positive staining for glial fibrillary acid protein (GFAP; Fig. 5). The cells were negative for epithelial membrane antigen (EMA) and Ki-67 labeling index was approximately 7%. P53 immunostaining was negative. Isocitrate dehydrogenase (IDH)1/2 gene analysis by polymerase chain reaction (PCR) sequencing did not reveal mutation. Based on these data, the diagnosis of low-grade astroblastoma was confirmed.

Discussion

Astroblastoma is one of the rarest central nervous system gliomas. It can occur in persons of any age, with a bimodal age distribution, with one peak in infancy (between 5 and
10 years) and the other one in young adults (between 21 and 30 years). The studies performed to date show a striking female preponderance with a male to female ratio of 1:11 [5–8, 18].

The tumor usually presents as a well-circumscribed and superficial mass, usually supratentorial with occipital and frontal lobes the most frequently affected sites. However, tumor invasion has also been reported into corpus callosum, cerebellum, brain stem, and optic nerve [1, 2, 6, 8].

Clinical signs and symptoms are dependent on the location and size of the tumor and primarily consist of those associated with elevated intracranial pressure. Headache, seizures, vomiting, and focal neurologic deficits are the most commonly mentioned symptoms [2, 4, 7].

Considerable confusion has surrounded the diagnosis, the histogenesis, and the classification of astroblastoma. Controversy still exists in the literature of the cell of origin of this neoplasm. Bailey and Bucy [11] believed that astroblastoma originated from astroblasts, an intermediate stage between glioblasts and astrocytes. However, Russell and Rubinstein [14] suggested that astroblastomas are dedifferentiated from mature astroglial cells. Later, in a study by Rubinstein and Herman [19], using electron microscopy, it was proven that astroblastomas might originate from persisting groups of embryonic precursor cells, transitional between astrocytes and ependymal cells. Given the lack of consensus, astroblastomas are currently classified as other neuroepithelial tumors by the WHO 2007 [16]; however, lack of sufficient clinicopathological data thwarts the WHO grading of these tumors [6].

On radiographic examination, the lesions show a characteristic appearance that may aid the pathologist in making the diagnosis of astroblastoma. On MRI, it is almost exclusively seen supratentorially and is peripheral in location. It typically appears as a large, well-demarcated, lobulated mass. It often has solid and cystic components with a characteristic bubbly appearance in the solid component, which was believed to result from the tumor vascular architecture, with inhomogeneous contrast enhancement and little vasogenic edema [1, 2, 4–6, 8, 9, 18]. It is hyperintense to white matter on fast fluid-attenuated inversion recovery (FLAIR) images and T2-weighted images and hypointense to isointense on T1-weighted images [1]. Our case showed a typical solid-cystic lesion with a bubbly appearance.

On macroscopic examination, astroblastomas were described as superficial, well-demarcated, lobulated, solid, or cystic masses [4].

On histologic examination, an astroblastoma is defined by the presence of perivascular pseudorosettes and prominent perivascular hyalinization. The perivascular pseudorosettes give the characteristic “cartwheel” appearance. They exhibit characteristic epithelioid cells with cytoplasmic processes having blunt-ended foot plates attached to the basal lamina of blood vessels [2, 6, 8, 9]. The amount of perivascular hyaline formation varies from case to case; but in the most severe forms, expansive, acellular hyalinized zones will be seen without any residual tumor architecture [9]. Another feature of diagnostic importance is lack of fibrillary background [6]. Astroblastic features must be present in all the tumor extension to make the diagnosis of astroblastoma [8]. This tumor is mostly well circumscribed. Higher grade lesions will occasionally have clusters of tumor cells extending marginally into surrounding brain; however, there are no reports of diffuse infiltration of the surrounding tissue [9]. In our case, prominent hyalinization of the capillary network occurred only focally.

Because astroblastoma exhibits a highly variable biological behavior, a WHO grade has not been established yet. Based on morphology, Bonnin and Rubinstein [20] reported two distinct histological types: prognostically favorable “low-grade/well-differentiated” and unfavorable
“high-grade/anaplastic” groups. The former includes astroblastomas with uniform perivascular arrangement of pseudorosettes, low to moderate numbers of mitotic figures, minimal cellular atypia, minimal to no vascular endothelial proliferation, and predominant sclerosis of the vascular walls. They are generally indolent and associated with a more favorable prognosis after surgical resections. The latter shows focal or multifocal regions of high cellularity, anaplastic nuclear features, high mitotic rates, vascular proliferation, and necrosis with pseudopalisading. They have shorter postoperative survival times. Our case was considered to be in the low-grade group as it had an orderly growth pattern with no evidence of necrosis, cellular atypia, high mitotic activity, or vascular endothelial proliferation.

Immunohistochemical features of astroblastoma have some variability throughout the literature. Immunostaining for GFAP is positive, lending support to the theory that the tumor cell is derived from an astrocyte cell line. Astroblasts also consistently stain positive with vimentin, suggesting derivation from a more primitive astroblast, and for S-100 protein. Other immunostains, such as neuron-specific enolase (NSE), EMA, cytokeratin (CK), and CAM 5.2, have had highly variable results in the current literature [2, 6, 9].

Apart from our case, 53 reported cases of astroblastoma are reviewed in this work. Epidemiological, clinical, radiologic, and immunohistochemical characteristics and grading are summarized in Table 1.

The diagnosis of astroblastoma is often difficult. In fact, astroblastic features are not unique to astroblastoma and can also be found in other tumors. Therefore, the combination of the radiologic and the histopathologic characteristics is necessary for making a correct diagnosis. The main differential diagnoses are ependymoma and angiocentric glioma [4, 8, 9, 18]. The distinguishing features between astroblastoma and ependymoma are shorter and broader cellular processes and hyalinized or even sclerosed blood vessels [1, 3, 8, 9]. Furthermore, between the pseudorosettes are rarified spaces, in contrast to the compact intravascular architecture of the ependymoma and the lack of fibrillarity in astroblastoma helps to distinguish its pseudorosettes from those found in ependymomas [9]. Ependymomas may show a similar immunohistochemical pattern, but GFAP immunoactivity in ependymomas is often more intense than that in astroblastomas [8]. The distinction with angiocentric glioma is not clear-cut, because this is an ill-defined tumor entity, characterized by perivascular distribution of bipolar and spindle cells, with mild pleomorphism, an infiltrative border, and lack of high-grade features. On immunohistochemical examination, it is typically positive with antibodies to GFAP, S-100 protein, and vimentin. A dot-like pattern of immunoreactivity to EMA has also been described [18, 21]. Gemistocytic astrocytomas and glioblastomas frequently contain focal areas of perivascular pseudorosettes. Therefore, the diagnosis of astroblastoma should be reserved for well-demarcated gliomas purely or mainly composed of the characteristic gliovascular structure described. The distinction between astroblastomas and nonglial papillary tumors such as papillary meningiomas and metastases from papillary tumors is aided by immunohistochemical features that show positive staining with glial markers such as GFAP and S-100 [8].

Data on the molecular genetics of astroblastoma are rare and only recently available from the literature. A study by Brat et al. [22] demonstrated that astroblastomas have characteristic chromosomal aberrations because they exhibit gain of chromosomes 19 and 20. These anomalies are different from those of the ependymomas or astrocytic tumors, suggesting that astroblastoma is a distinct entity rather than a variant of ependymoma [1, 4]. Other alterations noted were losses on 9q, 10, and X chromosome [22]. Shuangshoti et al. [23] found loss of heterozygosity at the D19S412 locus on 19q in a cerebral astroblastoma. More recently, an absence of IDH 1/2 and TP53 mutations, which are known to be involved in the development of low-grade gliomas, was shown in astroblastomas [24, 25]. In this case, there was not IDH1 mutation. P53 immunostaining was negative.

Since astroblastomas are rare and tumor descriptions in the literature concern only individual cases or small collections of cases, optimal treatment protocols have not been established. Total resection is the best treatment. It provides excellent tumor control rates [1, 2]. Subtotal resection should be avoided, if possible [26]. The addition of adjuvant focal radiotherapy after subtotal resection does not appear to provide equivalent outcomes to gross total resection. Adjuvant therapy for high-grade and recurrent cases is recommended [4, 6, 26]. Regular follow-up is required even in low-grade variants due to unpredictable behavior. Favorable prognosis is almost invariably associated with well-circumscribed tumors which permit total resection of tumor in all grades [2].

Several investigators have found that astroblastoma prognosis may be predicted by the histology and extent of resection. The low-grade astroblastomas are thought to have a better prognosis than the high-grade ones. Their prognosis is similar to that of low-grade gliomas. High-grade astroblastoma prognosis corresponds to that of anaplastic astrocytomas and has been associated with recurrence and progression [1, 8]. Ahmed et al. [7] presented the largest series of patients with astroblastoma described in the literature (n = 239). They found that older age, supratentorial location, and treatment prior to
| Reference         | Age/Gender | Location | Symptoms                  | MRI                                                                 | Immunohistochemistry | Grade |
|-------------------|------------|----------|---------------------------|---------------------------------------------------------------------|-----------------------|-------|
| Thiessen et al. (1998) [27] | 5; F       | PL       | Seizures                  |                                                                     | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Thiessen et al. (1998) [27] | 51; F      | FL       | Seizures                  |                                                                     | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Thiessen et al. (1998) [27] | 5; F       | PL       | Diplopia, headaches       | Cystic, contrast-enhancing mass with a ring of contrast enhancement and a peritumoral edema | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Thiessen et al. (1998) [27] | 16; F      | POL      | Headaches                 |                                                                     | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Thiessen et al. (1998) [27] | 5; F       | POL      | Headaches                 |                                                                     | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Thiessen et al. (1998) [27] | 1; F       | FL       | Seizures                  |                                                                     | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Thiessen et al. (1998) [27] | 5; M       | TL       | Seizures                  |                                                                     | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Port et al. (2002) [5]  | 30; M      | FL       | Seizures                  | Well-circumscribed, lobulated mass with cystic and bubbly solid components and intense heterogeneous enhancement | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Port et al. (2002) [5]  | 42; F      | TL       | Seizures                  | Well-circumscribed, lobulated mass with cystic and bubbly solid components and with calcifications | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Port et al. (2002) [5]  | 24; F      | TL       | Seizures                  | Well-circumscribed, lobulated mass with cystic and bubbly solid components | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Port et al. (2002) [5]  | 5; F       | Supratentorial | Seizures                  | Solid and cystic mass with intense heterogeneous enhancement of the solid portion and rim enhancement of the cystic portion | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Port et al. (2002) [5]  | 3; F       | Supratentorial | Seizures                  | Well-circumscribed, heterogeneous mass with bubbly appearance and heterogeneous enhancement of the solid component and with cystic changes | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Port et al. (2002) [5]  | 15; F      | Corpus callosum | Seizures                  | Solid and cystic mass with heterogeneous enhancement of the solid portion and rim enhancement around the cystic portion | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Sugita et al. (2002) [28] | 33; F      | FL       | Seizures                  | Enhancing lesion mass                                               | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | HG    |
| Cabrera-Zubizarreta et al. (2002) [29] | 18; F      | FL       | Motor deficit, headaches, diplopia | Well-circumscribed heterogeneous mass with solid and cystic areas | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Kim et al. (2004) [30]   | 15; F      | FL       | Headaches, diplopia, nasal hemianopia |                                                                     | EMA, VIM, GFAP, PS100, NF, CK, Ki67                            | LG    |
| Reference                  | Age/Gender | Location | Symptoms                           | MRI                                                                 | Immunohistochemistry | Grade |
|----------------------------|------------|----------|------------------------------------|---------------------------------------------------------------------|-----------------------|-------|
| Caroli et al. (2004) [31]  | 30; M      | TL       | Coma                               | Well-demarcated mass with cystic changes and with inhomogeneous enhancement after an injection of gadolinium | ++                   | 8%    | HG   |
| Kaji et al. (2006) [32]    | 17; M      | Frontal operculum | Diploia, headaches, hemiparesis | Tumor with inhomogeneous enhancement | ++ ++ ++ ++ | 5.6% | LG   |
| Lau et al. (2006) [33]     | 21; F      | Parietal | PL                                 | Solid and cystic mass with homogeneous enhancement after gadolinium | ++ ++ ++ >5% |       |      |
| Miranda et al. (2006) [34] | 42; F      | FL       | Headache, seizure                  | Well-defined, lobulated, contrast-enhancing mass with cystic change | ++ ++ +           | 4%    | HG   |
| Hata et al. (2006) [35]    | 16; F      | PL       | Headaches                          | Well-defined solid cystic mass with a heterogenous contrast enhancement | ++ + +       | ≈7%   | HG   |
| Kubota et al. (2006) [36]  | 8; F       | FPL      | Headache, deterioration of consciousness level, motor weakness | Heterogeneously enhanced large circumscribed round mass with peritumoral edema | + ++ – +       | 15.6% | HG   |
| Araoj et al. (2007) [8]    | 33; M      | TL       | Headache, nausea                   | Highly vascular hemorrhagic lesion with edema and heterogeneous contrast enhancement | – ++ +         | 15%   | HG   |
| Notarianni et al. (2008) [9] | 20; F     | Brainstem | Headaches, numbness, diplopia, blurred vision, ataxia | Well-circumscribed, contrast-enhancing cystic lesion | ++ + + + – + | ≈7%   | ?    |
| Eom et al. (2008) [1]      | 20; F      | TL       | Headache                           | Isointense mass with bubble-like appearance, little peritumoral edema, cleft-like area and a strong heterogeneous contrast enhancement after contrast injection | ++ ++ + ++ + | 16%   | HG?  |
| Fathi et al. (2008) [37]   | 53; M      | PL       | Lethargy, headaches, impairment of memory and word finding, unsteady gait | Remarkably circumscribed, contrast-enhancing mass with perifocal edema | – ++ ++ ++ – – | <1%; 4% in the recurrent tumor | LG   |
| Unal et al. (2008) [38]    | 4; M       | FPL      | Deficits of balance and difficulty with walking | Cystic mass with solid mural nodule, little peritumoral edema, and heterogeneous contrast enhancement | – ++ ++ + – | 8%    | HG   |
| Salvati et al. (2009) [39] | 30; M      | TL       | Intracranial hypertension          | Cystic circular lesion with inhomogeneous enhancement and very light edema | + ++           | 8%    | HG   |
| Salvati et al. (2009) [39] | 27; F      | POL      | Seizure                            | Cystic mass with solid mural nodule, little peritumoral edema, and heterogeneous contrast enhancement | + ++           | 8%    | HG   |
| Salvati et al. (2009) [39] | 39; F      | TL       | Aphasia                            | Cystic mass with solid mural nodule, little peritumoral edema, and heterogeneous contrast enhancement | + ++           | 8%    | HG   |
| Salvati et al. (2009) [39] | 43; F      | FL       | Hemiparesis                        | Circular lesion with a ring-shaped contrast enhancement               | + ++           | 8%    | HG   |
| Reference                    | Age/Gender | Location     | Symptoms                                                                                                                                      | MRI                                                                 | Immunohistochemistry                                                                 | Grade |
|-----------------------------|------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------|
| Salvati et al. (2009) [39]  | 33; M      | Rolandic area| Hemiparesis                                                                                                                                   |                                                                      | + ++                                                                                  | HG    |
| Salvati et al. (2009) [39]  | 50; F      | OL           | Hemianopsia                                                                                                                                   |                                                                      | + ++                                                                                  | HG    |
| Kemerdere et al. (2009) [40]| 6; F       | FPL          | Nausea, vomiting, loss of balance and falls, hemiparesis, facial nerve palsy                                                                 | Prominently cystic mass containing solid parts with heterogeneous enhancement after gadolinium injection | ++ ++ + + 7% +                                                                   | HG    |
| Kemerdere et al. (2009) [40]| 7; F       | PL           | Seizure                                                                                                                                       | Solid mass with prominent gadolinium enhancement                       | ++ ++ 5%                                                                            | HG    |
| Mastrangelo et al. (2010) [41]| 21; F     | FPL          | Headaches, vomiting                                                                                                                           |                                                                      | ++ ++ + 30%                                                                          | HG    |
| Mastrangelo et al. (2010) [41]| 12; F     | TL           | Headaches                                                                                                                                     | Contrast-enhancing, well-defined lobulated mass, with little peritumoral edema and multiple cysts included in the solid component | – ++ + 5–10%                                                                        | HG    |
| Bergkåsa et al. (2011) [3]  | 50; F      | FL           | Seizures                                                                                                                                      | Well-circumscribed mass with patchy contrast enhancement              | − ++ ++ + 10%                                                                      | HG    |
| Bhattacharjee et al. (2011) [42]| 4; F    | POL          | Irregularity of the bone over the parietal region, headache                                                                              | Solido-cystic lesion with heterogeneous enhancement after gadolinium injection and bone erosion | − ++ ++ 15%                                                                        | HG    |
| Agarwal et al. (2012) [3]   | 12; F      | PL           | Headache, diplopia                                                                                                                             | Well-demarcated mass with peripheral contrast enhancement              | ++ ++                                                                                | LG    |
| Khosla et al. (2012) [43]   | 11; F      | FPL          | Headache, vomiting, blurring of vision, seizures                                                                                             | Well-defined solid cystic mass with a strong heterogenous contrast enhancement | + + + 4%                                                                           | HG    |
| Nasit and Trivedi (2013) [44]| 10; F     | FPL          | Headaches, seizures                                                                                                                           | Lobulated well-defined solido-cystic lesion with thick and intense peripheral contrast enhancement and edema | − ++ ++ − − 0.5%                                                                  | LG    |
| De la Garma et al. (2014) [45]| 9; F      | FPL          | Headaches, nausea, vomiting, hemiparesis, seizures, aphasia                                                                               | Multicystic lesion with bubbly heterogenous pattern with minimal edema and a mixed solid and peripheral rim enhancement after contrast injection | + ++ + 40%                                                                         | HG    |
| Janz and Buhl (2014) [17]   | 16; F      | POL          | Headaches, nausea, dizziness, vomiting                                                                                                       | Hyointense lesion in T1-WI with peritumoral edema and peripheral, heterogenous bubbly enhancement | ++ +                                                                                  | LG with transition to HG |
| Janz and Buhl (2014) [17]   | 24; F      | TL           | Headaches, seizures                                                                                                                           | Partly cystic mass with rim contrast enhancement of media and limited perifocal edema | ++ + + focally > 30%                                                              | HG    |
| Singh et al. (2014) [6]     | 12; F      | PL           | Seizures, headache, vomiting                                                                                                                | Well-defined hyperintense, contrast-enhancing cystic lesion with mural nodule | ++ ++ ++                                                                          | LG    |
| 36; M                       | OTL        | Headaches, nausea, vomiting                                                                                                                |                                                                      | − + + − − < 2%                                                                      | LG    |
| Reference       | Age /Gender | Location | Symptoms                                      | MRI                                                                 | Immunohistochemistry | Grade |
|-----------------|-------------|----------|-----------------------------------------------|----------------------------------------------------------------------|----------------------|-------|
| Yao et al. (2015) | 16, M       | OTL      | Headaches, vomiting                           | Heterogenous mass with solid and cystic components with perilesional edema and calcifications | – + + + – 2–4% < 10% | LG    |
| Narayan et al. (2015) | 40; M       | FL       | Headache, nausea, vomiting, confusion         | Well-demarcated enhancing, partially cystic, partially calcified lesion | + ++ ++ ++            | ?     |
| Singla et al. (2016) | 30; F       | FL       | Headaches, altered sensorium, weakness        | Well-defined spherical lesion with edema and hemorrhage              |                     | LG    |
| Singla et al. (2016) | 11; M       | FPL      | Seizures                                      | Lobulated lesion heterogeneously enhanced with gadolinium            |                     | HG    |
| Yuzawa et al. (2016) | 18, F       | FPL      | Headache, nausea, numbness in the face and upper limb | Well-circumscribed, solid, and cystic lesion with a bubbly appearance, little perilesional edema, and marked contrast enhancement | ++ ++ + + 10.8%     | LG    |
| Yeo et al. (2016) | 35; M       | Lateral ventricle | Limb numbness and weakness             | Lobulated, heterogenous mass                                        | ++                   | LG    |
| Our case        | 8; F        | OTL      | Seizure, headaches, decreased visual acuity   | Well-demarcated mass with a multicystic component, bubbly appearance, a strong contrast enhancement after contrast injection, and peritumoral edema | – + 7% –             | LG    |

- negative immunostaining, + focal immunostaining, ++ diffuse immunostaining, CK cytokeratin, EMA epithelial membrane antigen, F female, FL frontal lobe, FPL fronto-parietal lobe, GFAP glial fibrillary acid protein, HG high grade, LG low grade, M male, MRI magnetic resonance imaging, NF neurofilament, OL occipital lobe, OTL occipito-temporal lobe, PL parietal lobe, POL parieto-occipital lobe, TL temporal lobe, VIM vimentin
1990 were poor prognostic factors. In addition, they thought the reason why patients with cerebellar tumors had better prognosis was that they might have earlier signs of increased intracranial pressure, leading to a quicker diagnosis and subsequently more timely treatment than their supratentorial counterparts. Similarly, better prognosis for patients diagnosed after 1990 might be related to multiple factors like advances in diagnostics and therapeutic modalities, such as MRI [4].

Conclusions
Astroblastoma is a very rare primary brain tumor. Its diagnosis is often challenging because of the astroblastic aspects that can be found in astrocytic tumors, in ependymomas, and in non-neuroepithelial tumors. Considerable confusion surrounds its histogenesis and classification. The low incidence rate makes it difficult to conduct studies to examine tumor characteristics.

Abbreviations
CK: Cytokeratin; EMA: Epithelial membrane antigen; FLAIR: Fluid-attenuated inversion recovery; GFAP: Glial fibrillary acid protein; IDH: Isocitrate dehydrogenase; MRI: Magnetic resonance imaging; NSE: Neuron-specific enolase; PCR: Polymerase chain reaction; WHO: World Health Organization

Acknowledgements
We thank Prof Afaf Amarti Riffi and Prof Audrey Rousseau who participated in establishing the diagnosis.

Funding
The authors received no specific funding for this study.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
NH, HE, and LC performed the histological examination of the tumor and were major contributors to writing the manuscript. NS and SB performed genetic analysis. MYAL performed the radiologic examination. EMC analyzed and interpreted the patient data and performed surgical resection. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient’s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pathology, Hassan II University Hospital, 30000 Fez, Morocco. 2Biomedical and Translational Research Laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco. 3Biocative Molecules Laboratory, Faculty of Science and Technology, Sidi Mohamed Ben Abdellah University, Fez, Morocco. 4Department of Radiology, Hassan II University Hospital, Fez, Morocco. 5Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco. 6Department of Neurosurgery, Hassan II University Hospital, Fez, Morocco.

Received: 10 July 2017 Accepted: 19 February 2018

Published online: 21 April 2018

References
1. Eom KS, Kim JM, Kim T-Y. A Cerebral Astroblastoma Mimicking an Extra-axial Neoplasm. J Korean Neurours Soc. 2008;43:205–8.
2. Agarwal V, Mally R, Palande DA, Velho V. Cerebral astroblastoma: A case report and review of literature. Asian J Neurours. 2012;78:98–100.
3. Bergkäa M, Sundström S, Gulati S, Torp SH. Astroblastoma – a case report of a rare neuroepithelial tumor with complete remission after chemotherapy. Clin Neuropathol. 2011;30(6):301–6.
4. Shen F, Chen L-c, Yu Y, Zhou L-F. Astroblastoma: Rare Incidence and Challenges in the Pattern of Care. World Neurours. 2014;82(1/2):e125–7.
5. Port JD, Brat DJ, Burger PC, Pomper MG. Astroblastoma: Radiologic Pathologic Correlation and Distinction from Ependymoma. Am J Neuroradiol. 2002;23:243–7.
6. Singh DK, Singh N, Singh R, Husain N. Cerebral astroblastoma: A radiopathological diagnosis. J Pediatr Neurol. 2014;4:45–7.
7. Ahmed KA, Allen PK, Mahajan A, Brown PD, Ghia AJ. Astroblastoma: a surveillance, epidemiology, and end results (SEER)-based patterns of care analysis. World Neurours. 2014;82:e291–7.
8. Alaraj A, Khan M, Oh S, Michalis E, Valiy-Nagy T, Hersonsky T. Astroblastoma presenting with intracerebral hemorrhage misdiagnosed as dural arteriovenous fistula: review of a rare entity. Surg Neurol. 2007;67:308–13.
9. Notarianne C, Akin M, Fowler M, Nanda A. Brainstem astroblastoma: a case report and review of the literature. Surg Neurol. 2008;69:201–5.
10. Bailey P, Cushing HA. A Classification of Tumors of the Glioma Group on a Histogenetic Basis with a Correlation Study of Diagnosis, 83–84. Philadelphia: PA; Lippincott; 1926. p. 133–6.
11. Bailey P, Bucy PC. Astroblastoma of the brain. Acta Psychiatr Neurol. 1930;5:439–45.
12. Kernohan JW, Mabon RF, Svien HJ, et al. A simplified classification of the gliomas. Proc Staff Meet Mayo Clin. 1949;24(3):8–13.
13. Zülch KJ. Biologie und Pathologie der Hirn Geschwülste [Biology and pathology of brain tumors]. In: Zülch KJ, Christensen E, editors. Pathologische Anatomie der Raummbeeingenden Intrakraniellen Prozesse. Berlin: Springer; 1956. p. 1.
14. Russell DS, Rubinstein LJ. Pathology of Tumours of the Nervous System. 5th ed. London: Edward Arnold; 1989.
15. Kubota T, Hirano A, Sato K, Yamamoto S. The fine structure of astroblastoma. Cancer. 1985;55(4):745–50.
16. Aldape KD, Rosenblum MK. Astroblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007. p. 88–9.
17. Janz C, Buhl R. Astroblastoma: Report of two cases with unexpected clinical behavior and review of the literature. Clin Neurol Neurosurg. 2008;112:95–101.
18. Mellai M, Piazzoli, P. Cytology, Cyst, and Malignancy. Cancer. 1985;55(4):745–50.
19. Rubinstein LJ, Herman MM. The astroblastoma and its possible cytogenic relationship to the tanycyte. An electron microscopic, immunohistochemical, tissue- and organ-culture study. Acta Neuropathol. 1989;78:45–50.
20. Bonnin JM, Rubinstein LJ. Astroblastomas: a pathological study of 23 tumors, with a postoperative follow-up in 13 patients. Neurosurgery. 1989;25:6.
21. Marburger T, Prayson R. Angiocentric Glioma: A Clinicopathologic Review of 5 Tumors With Identification of Associated Cortical Dysplasia. Arch Pathol Lab Med. 2011;135(8):1037–41. 1989.
22. Brat DJ, Hirose Y, Cohen KF, Feuerstein BG, Burger PC. Astroblastoma: clinicopathologic features and chromosomal abnormalities defined by comparative genomic hybridization. Brain Pathol. 2000;10:342–52.
23. Shuangshoti S, Mitphraphan W, Kanvisetsri S, et al. Astroblastoma: report of a case with microsatellite analysis. Neuropathology. 2000;20:228–32.
24. Camelo-Pitagua S, Jansen M, Ganguly A, Kim JC, Cooper AK, Dias-Santagata D, Nuff CL, Iafate AJ, Louis DN. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol. 2011;70:101–5.
25. Fu YJ, Taniguchi Y, Takeuchi S, Shiga A, Okamoto K, Hirato J, Nobusawa S, Nakazato Y, Kakita A, Takahashi H. Cerebral astroblastoma in an adult: an immunohistochemical, ultrastructural and genetic study. Neuropathology. 2013;33:312–9.

26. Sughrue ME, Choi J, Rutkowski MJ, Aranda D, Kane AJ, Barani U, Pana AT. Clinical features and post-surgical outcome of patients with astroblastoma. J Clin Neurosci. 2011;18:750–4.

27. Thiesen B, Finlay J, Kulkarni R, et al. Astroblastoma: does histology predict biological behavior? J Neuro-Oncol. 1998;40:59–65.

28. Sugita Y, Terasaki M, Shigemori M, et al. Astroblastoma with unusual signet-ring-like cell components: a case report and literature review. Neuropathology. 2002;22:200–5.

29. Cabrera-Zubizarreta A, Catón B, Martínez de Guereñu B, et al. Low grade astroblastoma: pathological findings and on magnetic resonance. Rev Neurol. 2002;34:936–9.

30. Kim DS, Park SY, Lee SP. Astroblastoma: A case report. J Korean Med Sci. 2004;19:772–6.

31. Caroli E, Salviati M, Esposiro V, et al. Cerebral astroblastoma. Acta Neurochir. 2004;146:629–33.

32. Kaji M, Takeshima H, Nakazato Y, et al. Low-grade astroblastoma recurring with extensive invasion—case-report. Neurol Med Chir. 2006;46:450–4.

33. Lau PP, Thomas TM, Lui PC, et al. ‘Low-grade’ astroblastoma with rapid recurrence: a case report. Pathology. 2006;38:78–80.

34. Miranda P, Lobato RD, Cabello A, Gómez PA, Martínez de Aragón A. Complete surgical resection of high-grade astroblastoma with long time survival: case report and review of the literature. Neurocirugia (Astur). 2006;17(1):60–3.

35. Hata N, Shono T, Yoshimoto K, et al. An astroblastoma case associated with loss of heterozygosity on chromosome 9p. J Neuro-Oncol. 2006;78:69–73.

36. Kubota T, Sato K, Arishima H, et al. Astroblastoma: immunohistochemical and ultrastructural study of distinctive epithelial and probable tanycytic differentiation. Neuropathology. 2006;26:72–81.

37. Fathi AR, Novoa E, El-Koussy M, et al. Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up. Pathol Res Pract. 2008;204:344–51.

38. Ural E, Koksal Y, Vajtai I, Toy H, Kocaogullar Y, Paksoy Y. Astroblastoma in a child. Childs Nerv Syst. 2008;24:165–8.

39. Salvati M, DElia A, Brogna C, et al. Cerebral astroblastoma: analysis of six cases and critical review of treatment options. J Neuro-Oncol. 2009;93:369–78.

40. Kemerdere R, Dashti R, Ulu MO, et al. Supratentorial high grade astroblastoma: report of two cases and review of the literature. Turk Neurosurg. 2009;19:149–53.

41. Mastrangelo S, Lauriola L, Cocca P, et al. Two cases of pediatric high-grade astroblastoma with different clinical behavior. Tumori. 2010;96:160–3.

42. Bhattachajjee S, Pulligopu AK, Uppin MS, et al. Astroblastoma with bone invasion. Asian J Neurosurg. 2011;6:113–5.

43. Khusla D, Yadav BS, Kumar R, Agrawal P, Patel NKFD, Sharma SC. Pediatric Astroblastoma: A Rare Case with a Review of the Literature. Pediatr Neurosurg. 2012;48:122–5.

44. Nasit JG, Trivedi P. Recurrent low-grade astroblastoma with signet ring-like cells and high proliferative index. Fetal Pediatr Pathol. 2013;32:284–92.

45. De la Garma VH, Arcipreste AA, Vazquez FP, Aguilar RR, Castruita UQ, Guerra RM. High-grade astroblastoma in a child: Report of one case and review of literature. Surg Neurol Int. 2014;5:111.

46. Yao K, Wu B, Xie M, Duan Z, Wang J, Qi X. Distant dissemination of mixed low-grade astroblastoma-arteriovenous malformation after initial operation: a case report. Int J Clin Exp Pathol. 2015;8(6):7450–6.

47. Barakat MI, Ammar MG, Salama HM, Abuhasher S. Astroblastoma: Case Report and Review of Literature. Turk Neurosurg. 2016;26(5):790–4.

48. Singla N, Dhandapani SS, Kapoor A, Chatterjee D, Vashishta Yeo RK. Hemorrhage in astroblastoma: An unusual manifestation of an extremely rare entity. J Clin Neurosci. 2016;25:147–50.

49. Yuzawa S, Nishihara H, Tanino M, Kimura T, Moriya J, Kamoshima Y, Nagashima K, Tanaka S. A case of cerebral astroblastoma with rhabdoid features: a cytological, histological, and immunohistochemical study. Brain Tumor Pathol. 2016;33(1):63–70.

50. Yeo JJY, Low YYS, Putti TC, Koh WMR. Adult intraventricular astroblastoma. Singap Med J. 2016;57(1):53–4.

Submit your next manuscript to BioMed Central and we will help you at every step:

• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit